the lungs, with significantly lower levels of respiratory disease and no lung damage compared to control animals, according to a recent article deposited in bioRxiv.69 Another adenoviral vector vaccine developed by CanSino Biological Inc. and Beijing Institute of Biotechnology using a genetically engineered replication-defective adenovirus type 5 vector to express the SARS-CoV-2 spike protein (Ad5-nCoV) is currently being tested in Phase I/II trials (NCT04398147, NCT04341389, NCT0431312).
Although vaccines based on novel DNA and mRNA technologies might be promising, there are no such kinds of